NCT02872987 GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial
| NCT ID | NCT02872987 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Goethe University |
| Condition | Acute Lymphoblastic Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2009-02 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2009-02 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The GMALL registry serves the purpose of ALL research and quality assurance. The Registry collects data about diagnostics, treatment and outcome of Adult ALL Patients in the clinical routine, whether or not the patient is treated within a clinical trial.
Eligibility Criteria
Inclusion Criteria: * Acute Lymphoblastic Leukemia (All Subtypes) if treated according to ALL protocols * Other Types of Leukemia (NK Cell Lymphoma/Leukemia, Biphenotypic Acute Leukemia) if treated according to ALL protocols * Non-Hodgkin's Lymphoma of Following Subtypes: Burkitt Lymphoma, B Cell Lymphoma, B- or T-lineage Lymphoblastic Lymphoma, Anaplastic Large Cell Lymphoma, Other NHL) if treated according to B-ALL protocols * Age minimum 18 yrs
Contact & Investigator
Nicola Gökbuget, Dr. med.
PRINCIPAL INVESTIGATOR
University Hospital of Frankfurt (Main)
Frequently Asked Questions
Who can join the NCT02872987 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Lymphoblastic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02872987 currently recruiting?
Yes, NCT02872987 is actively recruiting participants. Contact the research team at goekbuget@em.uni-frankfurt.de for enrollment information.
Where is the NCT02872987 trial being conducted?
This trial is being conducted at Graz, Austria, Leoben, Austria, Vienna, Austria, Frankfurt am Main, Germany and 11 additional locations.
Who is sponsoring the NCT02872987 clinical trial?
NCT02872987 is sponsored by Goethe University. The principal investigator is Nicola Gökbuget, Dr. med. at University Hospital of Frankfurt (Main). The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.